Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.72 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12494539 | 0.95 | PIM1 (0.91) | PIM1PIM2PIM3 | |
| SCHEMBL2176614 | 0.91 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL2179124 | 0.89 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL12492855 | 0.84 | PIM2 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL12496028 | 0.83 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL2179053 | 0.83 | PIM3 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL2178491 | 0.82 | PIM1 (0.84) | PIM1PIM2PIM3 | |
| SCHEMBL2179630 | 0.82 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL2179649 | 0.82 | PIM2 (0.92) | PIM1PIM2PIM3 | |
| SCHEMBL12493581 | 0.81 | PIM1 (0.84) | PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682991-B2 | Tricyclic compounds for use as kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2017-06-20 | — | — | US | claimed |
| US-9682991-B2 | Tricyclic compounds for use as kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2017-06-20 | — | — | US | disclosed |
| US-9682991-B2 | Tricyclic compounds for use as kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2017-06-20 | — | — | US | disclosed |
| US-9682991-B2 | Tricyclic compounds for use as kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2017-06-20 | — | — | US | disclosed |
| EP-2519526-B1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2519526-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080510-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.